The Chondrosarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chondrosarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Chondrosarcoma by 25 companies/universities/institutes. The top development phase for Chondrosarcoma is phase ii with 17 drugs in that stage. The Chondrosarcoma pipeline has 26 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chondrosarcoma pipeline products market are: Bristol-Myers Squibb, Pharma Mar and BioMed Valley Discoveries.
The key targets in the Chondrosarcoma pipeline products market include Programmed Cell Death Protein 1, Tyrosine Protein Kinase Receptor UFO, and Isocitrate Dehydrogenase [NADP] Mitochondrial.
The key mechanisms of action in the Chondrosarcoma pipeline product include Programmed Cell Death Protein 1 Antagonist with five drugs in Phase III. The Chondrosarcoma pipeline products include 13 routes of administration with the top ROA being Intravenous and nine key molecule types in the Chondrosarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Chondrosarcoma overview
Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination. Treatment includes chemotherapy and radiation therapy.
For a complete picture of Chondrosarcoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
